Table 5.
Risk factors tested for association with 5-FU- and capecitabine-associated cardiotoxicity
| Variable | Patients with cardiotoxicity (n = 161) | Patients without cardiotoxicity (n = 366) | P |
|---|---|---|---|
| Chemotherapy | |||
| 5-Fluorouracil | 49 (30.4) | 147 (40.2) | 0.033 |
| Capecitabine | 112 (69.6) | 219 (59.8) | |
| Chemotherapy cycle | |||
| 1–4 | 53 (32.9) | 143 (39.1) | 0.386 |
| 5–9 | 91 (56.5) | 177 (48.4) | |
| ≥ 9 | 9 (5.6) | 26 (7.1) | |
| UK | 8 (5.0) | 20 (5.5) | |
| Concurrent radiotherapy | |||
| Yes | 6 (3.7) | 16 (4.4) | 0.733 |
| No | 155 (96.3) | 350 (95.6) | |
| Sex | |||
| Male | 108 (67.1) | 240 65.6) | 0.737 |
| Female | 53 (32.9) | 126 (34.4) | |
| Age, years | |||
| ≤ 29 | 4 (2.5) | 6 (1.6) | 0.257 |
| 30~ | 9 (5.6) | 23 (6.3) | |
| 40~ | 33 (20.5) | 79 (21.6) | |
| 50~ | 40 (24.8) | 110 (30.1) | |
| 60~ | 54 (33.5) | 124 (33.9) | |
| 70~ | 19 (11.8) | 23 (6.3) | |
| 80~ | 2 (1.2) | 1 (0.3) | |
| Pre-existing disease | |||
| Hypertension | |||
| Yes | 44 (27.3) | 62 (16.9) | 0.006 |
| No | 117 (72.7) | 304 83.1) | |
| Diabetes | |||
| Yes | 11 (6.8) | 18 (4.9) | 0.375 |
| No | 150 (93.2) | 348 (95.1) | |
| Cardiac disease | |||
| Yes | 9 (5.6) | 4 (1.1) | 0.004 |
| No | 152 (94.4) | 362 (98.9) | |
| Hyperlipidemia | |||
| Yes | 2 (1.2) | 2 (0.5) | 0.762 |
| No | 159 (98.8) | 364 (99.5) | |
| Surgical history | |||
| Yes | 129 (80.1) | 286 (78.1) | 0.608 |
| No | 32 (19.9) | 80 (21.9) | |
| Treatment history | |||
| Chemotherapy | |||
| Yes | 33 (20.5) | 85 (23.2) | 0.521 |
| No | 128 (79.5) | 281 (76.8) | |
| Radiotherapy | |||
| Yes | 9 (5.6) | 23 (6.3) | 0.759 |
| No | 152 (94.4) | 343 (93.7) | |
| Chemotherapy and radiotherapy | |||
| Yes | 7 (4.3) | 19 (5.2) | 0.808 |
| No | 154 (95.7) | 347 (94.8) | |